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ExtEndEd rEport
Efficacy and safety of abatacept, a T-cell modulator, 
in a randomised, double-blind, placebo-controlled, 
phase III study in psoriatic arthritis
philip J Mease,1 Alice B Gottlieb,2 désirée van der Heijde,3 oliver FitzGerald,4 
Alyssa Johnsen,5 Marleen nys,6 Subhashis Banerjee,5 dafna d Gladman7
ABSTRACT
Objectives to assess the efficacy and safety of 
abatacept, a selective t-cell costimulation modulator, in a 
phase III study in psoriatic arthritis (psA).
Methods this study randomised patients (1:1) with 
active psA (~60% with prior exposure to a tumour 
necrosis factor inhibitor) to blinded weekly subcutaneous 
abatacept 125 mg (n=213) or placebo (n=211) for 24 
weeks, followed by open-label subcutaneous abatacept. 
patients without ≥20% improvement in joint counts 
at week 16 were switched to open-label abatacept. 
the primary end point was the proportion of patients 
with ≥20% improvement in the American College of 
rheumatology (ACr20) criteria at week 24.
Results Abatacept significantly increased ACr20 
response versus placebo at week 24 (39.4% vs 22.3%; 
p<0.001). Although abatacept numerically increased 
Health Assessment Questionnaire–disability Index 
response rates (reduction from baseline ≥0.35) at 
week 24, this was not statistically significant (31.0% 
vs 23.7%; p=0.097). the benefits of abatacept were 
seen in ACr20 responses regardless of tumour necrosis 
factor inhibitor exposure and in other musculoskeletal 
manifestations, but significance could not be attributed 
due to ranking below Health Assessment Questionnaire–
disability Index response in hierarchical testing. However, 
the benefit on psoriasis lesions was modest. Efficacy was 
maintained or improved up to week 52. Abatacept was 
well tolerated with no new safety signals.
Conclusions Abatacept treatment of psA in this phase 
III study achieved its primary end point, ACr20 response, 
showed beneficial trends overall in musculoskeletal 
manifestations and was well tolerated. there was only a 
modest impact on psoriasis lesions.
Trial registration number  Clinicaltrials. gov number, 
nCt01860976 (funded by Bristol-Myers Squibb).
InTROduCTIOn
Psoriatic arthritis (PsA) is an inflammatory arthritis 
that occurs in up to one-third of patients with 
psoriasis and is usually diagnosed years after the 
appearance of psoriatic skin disease.1 2 Although 
current treatments for PsA benefit many patients, 
a substantial proportion do not achieve significant 
improvement in their disease.3–5 Consequently, 
there remains an unmet need for effective and 
well-tolerated treatments.
PsA is associated with specific major histo-
compatibility complex class I molecules that are 
involved in antigen presentation to T cells, which 
are implicated in disease pathogenesis.6 Abatacept, 
a selective T-cell costimulation modulator, is a 
soluble fusion protein comprising the extracellular 
domain of human cytotoxic T-lymphocyte-asso-
ciated antigen-4 linked to the modified Fc (hinge, 
CH2 and CH3 domains) portion of human immu-
noglobulin G1.7 8 By selectively modulating the 
CD28 costimulatory signal required for full T-cell 
activation, abatacept blocks the process that trig-
gers the inflammatory cascade and, therefore, is a 
potential therapy for PsA with a distinct mechanism 
of action upstream of currently available agents.4 7 
Abatacept is an approved treatment for rheumatoid 
arthritis (RA) and juvenile idiopathic arthritis, with 
an established acceptable safety profile.9–14
Data have previously been reported from a phase 
II, dose-ranging study of abatacept in patients with 
active PsA and prior exposure to disease-modifying 
antirheumatic drugs (DMARDs), 37% of whom 
had previously received tumour necrosis factor 
inhibitor (TNFi). At 6 months, the dose of 10 mg/
kg given intravenously every 4 weeks showed the 
greatest increase in the proportion of patients with 
≥20% improvement in the American College of 
Rheumatology criteria (ACR20) versus placebo 
(48% vs 19%, respectively; p=0.006).15 The 
proportion of patients achieving a Health Assess-
ment Questionnaire–Disability Index (HAQ-DI) 
response (reduction from baseline score ≥0.3) 
at 6 months was also increased in the 10 mg/kg 
group versus placebo (45% vs 19%, respectively). 
In addition, trends towards improvements over 
placebo were seen in joint damage, based on MRI. 
Following these results, the phase III Active PSori-
aTic Arthritis RAndomizEd TriAl (ASTRAEA) Study 
was conducted to assess the efficacy and safety of 
abatacept in patients with active PsA, using a more 
convenient subcutaneous 125 mg weekly dose that 
has shown therapeutic equivalence to intrave-
nous dosing with 10 mg/kg every 4 weeks in RA.16
MeThOdS
Study design and oversight
This ongoing phase III study (total study dura-
tion including long-term extension, 729 days) 
was initiated in June 2013 and conducted across 
76 centres worldwide ( ClinicalTrials. gov number, 
NCT01860976). Clinical and radiographic database 
locks were in August and October 2015 (24-week 
analysis) and in March and April 2016 (1-year anal-
ysis), respectively. Using a central interactive voice 
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response system, patients were randomly assigned (1:1) in a 
double-blind manner to receive subcutaneous abatacept 125 mg 
weekly or matched placebo for 24 weeks. Randomisation was 
stratified globally (rather than at site level) by factors that were 
considered to potentially impact results, including current 
methotrexate use, prior TNFi use and whether plaque psoriasis 
involved ≥3% of body surface area (BSA). Within each stratum, 
permuted block randomisation was conducted with a block size 
of two. Patients who had not achieved ≥20% improvement in 
swollen and tender joint counts from baseline to week 16 were 
switched to open-label abatacept weekly (early escape (EE)) 
for 28 weeks (total study time for these patients, 44 weeks). At 
week 24, all remaining patients transitioned to the open-label 
period and received subcutaneous abatacept weekly for 28 weeks 
(total study time, 52 weeks). At the end of the open-label period, 
patients had the option of entering a 1-year, long-term extension.
The study was conducted in accordance with the Declaration 
of Helsinki, International Conference on Harmonisation Guide-
lines for Good Clinical Practice and local regulations. An Institu-
tional Review Board or Independent Ethics Committee approved 
the protocol, consent form and any other written information 
provided to patients. Patients were evaluated by the investiga-
tors, and the data were collected and analysed by Bristol-Myers 
Squibb under the direction of the investigators.
Patients
Enrolled patients were aged ≥18 years, met the classifica-
tion criteria for PsA17 and had active arthritis (≥3 swollen 
and ≥3 tender joints), active plaque psoriasis with ≥1 quali-
fying target lesion ≥2 cm in diameter and inadequate response 
or intolerance to ≥1 non-biologic DMARD. Concomitant treat-
ment with methotrexate, leflunomide, sulfasalazine or hydroxy-
chloroquine, non-steroidal anti-inflammatory drugs and oral 
corticosteroids (<10 mg/day) and use of low-potency topical 
corticosteroids in sensitive areas were permitted (as detailed 
in online section 1 in the supplementary appendix). To reflect 
a typical patient population in clinical practice and that of the 
phase II study,15 both TNFi-naïve and TNFi-exposed patients 
were enrolled. All patients gave written informed consent prior 
to study entry.
Assessments
Arthritis was assessed in 66 joints for swelling and 68 joints 
for tenderness by ACR response criteria for per cent improve-
ment from baseline18 and post hoc by the Disease Activity Score 
(DAS)28 (C-reactive protein (CRP)).19 Enthesitis at six loca-
tions was evaluated using the Leeds Enthesitis Index (range 
0–6)20 and dactylitis by the number of tender and swollen digits 
with a circumference ≥10% greater than the contralateral digit 
according to the Leeds Dactylitis Index basic score.21 Physical 
function was measured using the HAQ-DI (range 0–3).22 Among 
patients with plaque psoriasis involving ≥3% BSA at baseline, 
skin lesions were assessed using the Psoriasis Area and Severity 
Index (PASI; range 0–72).23 PsA disease activity was assessed 
using the minimal disease activity (MDA) criteria,24 the modi-
fied Composite Psoriatic Disease Activity Index,25 the Psoriatic 
Arthritis Disease Activity Score26 and post hoc for the Disease 
Activity index for Psoriatic Arthritis (DAPSA).27 Quality of life 
was evaluated using the Short Form-36 (SF-36)28 and the Derma-
tology Life Quality Index.29
Plain radiographs of hands and feet were taken at baseline and 
at weeks 24 and 52 (or weeks 16, 24 and 44 for EE patients). 
Radiographs were scored independently by two central, trained 
assessors (and an adjudicator in predefined cases) with experi-
ence using the PsA-modified Sharp–van der Heijde (SHS) scoring 
method (total score 0–528).30 Assessors were blinded to patient 
identity, treatment, clinical data and order of radiographs. 
Initially, baseline and week 24 (week 16 for EE) radiographs 
were scored; in a second round, all radiographs, including week 
52 (week 44 for EE), were scored. For joint erosion, joint space 
narrowing and total score, and the proportion of non-progres-
sors, the mean of the scores from two assessors was used. If one 
score was missing, then the available score was used. If required, 
an adjudicator reviewed the images, and the mean of the adjudi-
cator’s total score and the other total score that was closer to the 
adjudicator’s score was used (>0=progressors, ≤0=non-pro-
gressors). Safety was evaluated throughout the study by moni-
toring of adverse events (AEs) and routine laboratory tests.
efficacy end points
The primary end point was the proportion of patients with 
ACR20 responses at week 24. Key secondary end points at 
week 24, in hierarchical order, were the proportions of patients 
with an HAQ-DI response (reduction from baseline, ≥0.35), 
an ACR20 response in the TNFi-naïve and TNFi-exposed 
subgroups and a radiographic non-progression (change from 
baseline score, ≤0) according to PsA-modified total SHS score. 
Other secondary end points at week 24 included the propor-
tion of patients with ≥50% and ≥70% improvement in ACR 
criteria (ACR50 and ACR70, respectively), the proportion who 
achieved ≥50% improvement in PASI score from baseline (PASI 
50) and the mean change from baseline in SF-36 physical and 
mental component summary scores. Prespecified exploratory 
end points and post hoc analyses are described in online section 
2 in the supplementary appendix.
Statistical analysis
A hierarchical testing procedure (ie, testing outcomes in a 
predefined order) was used for the primary and key secondary 
end points to ensure preservation of the overall type I error. All 
estimates used for the sample size determination were based on 
the results of the phase II study of abatacept in PsA,15 except for 
non-progressors using PsA-modified total SHS score. A two-sided 
continuity corrected χ2 test at alpha=0.05 was used. To achieve 
≥80% power for each of the hierarchical end points and PASI 
50 responders, recruitment of 400 patients was required: 152 
(38%) and 248 (62%) in the TNFi-naïve and TNFi-exposed 
subgroups, respectively (see online section 3 in the supplemen-
tary appendix).
All efficacy analyses (including those up to week 44 or 52) 
were conducted using the intent-to-treat (ITT) population, 
which comprised all randomised patients who received at least 
one dose of study medication. Comparisons between treat-
ment arms were performed for the primary and key secondary 
end points, and PASI 50 responders at week 24, using a 
two-sided Cochran-Mantel-Haenszel χ2 test, stratified by 
current methotrexate use, prior TNFi use and plaque psoriasis 
involving ≥3% of BSA, at a 5% significance level for gener-
ating p values. The p values that did not control for overall type 
I error (nominal p values) were provided for end points that 
ranked lower in the statistical hierarchy than the first end point 
that was non-statistically significant at the 5% level, and for 
PASI 50 response, MDA and DAPSA score at week 24. For other 
end points, only 95% CIs of differences between abatacept and 
placebo arms were generated without obtaining p values. For 
binary responder analyses during the double-blind period, EE 
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patients at week 16 were imputed as non-responders at weeks 
20 and 24 (for radiographic analysis, EE patients were imputed 
as progressors at week 24). Patients who discontinued treatment 
were imputed as non-responders/radiographic progressors at all 
subsequent visits. Continuous variables for the double-blind 
analysis were assessed using a longitudinal repeated-measures 
analysis, imputing EE patients as missing beyond week 16 (see 
online section 3 in the supplementary appendix). In addition, 
if there were still missing data (for EE patients between week 4 
and week 16 and for non-EE patients between week 4 and week 
24), patients were imputed as non-responders at the time point 
with missing data. However, if data were missing between two 
time points at which the patient had a response (eg, ACR20), 
then in such cases the response (eg, ACR20) was imputed at the 
time point with missing data.
Analyses up to week 44/52 used actual data at each time 
point for EE and non-EE patients. A non-responder imputation 
was done for all missing values regardless of escape status. As 
mentioned above, the denominators for all responder analyses up 
to week 44/52 were equal to all randomised and treated patients 
(ITT population). Most efficacy end points are reported only up 
to week 44, at which time EE patients had received 28 weeks and 
non-EE patients had received 20 weeks of open-label treatment. 
However, for analyses of enthesitis, dactylitis and radiographic 
data, week 44 data from EE patients were combined with week 
52 data from non-EE patients, as these data were not collected 
at week 44 for non-EE patients. Continuous variables were anal-
ysed for this period using the longitudinal repeated-measures 
analysis model using the actual data including all patients in the 
ITT population. For SHS scores, adjusted mean change from 
baseline up to week 44/52 was calculated using the longitudinal 
repeated measures analysis model with the actual values for EE 
and non-EE patients (ITT population).
ReSulTS
Patients
In total, 424 randomised patients received at least one dose of 
abatacept (n=213) or placebo (n=211). Patient characteristics 
at baseline are shown in table 1. The overall mean (SD) age was 
50.4 (11.0) years, 55% were female and 60% reported current 
methotrexate use, with a mean (SD) dose of 17.1 (8.2) mg/
week at baseline. Most patients (~60%) had previously received 
TNFi agents; of these, most (abatacept 60%, placebo 62%) had 
failed at least one TNFi due to inadequate efficacy. Overall, 69% 
of patients had psoriasis covering ≥3% of BSA. Numbers of 
non-biologic DMARDs used prior to study entry are described 
in online table 1 in the supplementary appendix. The baseline 
disease characteristics included mean (SD) disease duration of 
8.5 (8.2) years; distal interphalangeal involvement in approxi-
mately half of the population (50.7%); presence of joint erosion 
on radiographs in 84% of patients, with a mean (SD) PsA-mod-
ified total SHS score of 18.8 (43.3); elevated serum CRP above 
upper limit of normal (3 mg/L) in 66% of patients, with a mean 
(SD) CRP of 14.1 (25.9) mg/L; and polyarticular disease in 98% 
of patients, with mean (SD) tender and swollen joint counts of 
20.2 (13.3) and 11.6 (7.5), respectively.
Patient disposition is shown in figure 1. A total of 76 (35.7%) 
and 89 (42.2%) patients in the abatacept and placebo groups, 
respectively, were assigned to EE and switched to open-label 
abatacept at week 16. From the original abatacept and placebo 
arms, 197 (92.5%) and 185 (87.7%) patients, respectively, 
entered the open-label period.
Musculoskeletal manifestations
Arthritis
Abatacept treatment resulted in a significantly higher propor-
tion of patients achieving an ACR20 response at week 24 versus 
placebo (39.4% vs 22.3%; p<0.001; table 2; figure 2; online 
table 2 in the supplementary appendix). The mean change from 
baseline in each of the ACR core components was numerically 
greater for patients in the abatacept group than those in the 
placebo group at 24 weeks (see online table 3 in the supplemen-
tary appendix).
As the effect of abatacept on the first key secondary end point 
in the statistical hierarchy (HAQ-DI response rate) did not reach 
significance (see below), only nominal p values were generated 
for subsequent outcomes. Nominally higher ACR20 response 
rates with abatacept versus placebo were seen in both TNFi-
naïve and TNFi-exposed subgroups at week 24 (table 2), with 
the largest treatment difference seen in TNFi-naïve patients. 
ACR20 responses at 24 weeks by number of prior TNFi received 
are shown in online table 4 in the supplementary appendix. 
Analysis (ITT population) up to week 44 showed that ACR20 
responses were maintained for patients who continued abatacept 
and improved for those who switched from placebo to abatacept 
(placebo/abatacept) in the total population and in both TNFi-
naïve and TNFi-exposed subgroups (table 2; figure 3; online 
table 5 in the supplementary appendix). Because the trial design 
allowed for early escape to open-label abatacept, improvement 
in the placebo-treated patients initiating active treatment would 
be expected starting at week 16. Similar trends were observed 
for ACR50 and ACR70 responses (table 2). In addition, patients 
with CRP elevated above the upper limit of normal at baseline 
showed the highest ACR20 responses at 24 weeks with abata-
cept treatment versus placebo (estimated differences (95% CI)): 
total population, 43.8% versus 23.7% (20.17 (9.32 to 31.02)); 
TNFi naïve, 50.0% versus 23.9% (26.09 (7.93 to 44.25)); TNFi 
exposed, 40.2% versus 23.5% (16.69 (3.21 to 30.17)).
The efficacy of abatacept in reducing arthritic manifestations 
was supported by the results of the post hoc analysis of greater 
improvement in DAS28 (CRP) from baseline to week 24 with 
abatacept versus placebo: adjusted mean change, –1.35 versus 
–0.94; adjusted difference (95% CI), –0.42 (–0.69 to –0.14). 
Continued improvement beyond week 24 in the ITT popula-
tion was seen in adjusted mean changes from baseline in DAS28 
(CRP) in both abatacept and placebo/abatacept groups, with 
changes from baseline to week 44 of –1.81 and –1.84, respec-
tively (see online supplementary figure 1 and table 6 in the 
supplementary appendix).
Enthesitis and dactylitis
At week 24, complete resolution of enthesitis and dactylitis 
present at baseline was numerically more frequent with abata-
cept versus placebo. The proportions (95% CI) of patients with 
enthesitis resolution were 32.9% (25.1 to 40.6) versus 21.2% 
(14.2 to 28.2) and with dactylitis resolution were 44.3% (31.8 
to 56.7) versus 34.0% (20.9 to 47.1), respectively. At week 
44/52, an increased proportion of patients achieved complete 
resolution of baseline enthesitis (48.6% vs 43.9%) and dactylitis 
(68.9% vs 60.0%) in both the abatacept and placebo/abatacept 
groups, respectively.
Physical function
The proportion of patients with an HAQ-DI response (reduc-
tion from baseline score ≥0.35) at week 24 was numerically 
higher with abatacept versus placebo: 31.0% versus 23.7%; 
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estimated difference (95% CI), 7.2 (–1.1 to 15.6); p=0.097. 
However, as this did not reach statistical significance, only 
nominal p values were generated for lower-ranking end points 
in the hierarchical testing. HAQ-DI responses at 24 weeks in 
the abatacept versus placebo arms were 34.5% versus 19.8%, 
respectively, in the TNFi-naïve subgroup (estimated difference 
14.8; 95% CI 1.7 to 28.0) and 28.7% versus 26.2%, respec-
tively, in the TNFi-exposed subgroup (estimated difference 2.5; 
95% CI –8.3 to 13.3). HAQ-DI responses were maintained to 
week 44 in the abatacept group and improved in the placebo/
abatacept group (39.9% and 38.9%, respectively) in the ITT 
population.
Further analyses showed nominal improvements in adjusted 
mean change in HAQ-DI score from baseline to week 24 with 
abatacept versus placebo for all patients: –0.33 versus –0.20, 
respectively; estimated difference (95% CI), –0.13 (–0.25 to 
–0.01), and in both TNFi-naïve (–0.29 vs –0.17) and TNFi-ex-
posed (–0.35 vs –0.18) subgroups. Continued improvements 
Table 1 Patient characteristics at baseline
Abatacept (n=213*) Placebo (n=211*)
demographic characteristics
Age, years  51.0 (10.7)  49.8 (11.3)
Sex, female, n (%) 121 (56.8) 112 (53.1)
Race, white, n (%) 195 (91.5) 198 (93.8)
Body mass index, kg/m2  30.7 (6.3)  31.3 (6.8)
Region, n (%)
South America  95 (44.6)  80 (37.9)
Europe  53 (24.9)  59 (28.0)
North America  44 (20.7)  40 (19.0)
Rest of World  21 (9.9)  32 (15.2)
disease characteristics
PsA duration, years   8.3 (8.1)   8.8 (8.3)
TJC  21.0 (13.4)  19.3 (13.1)
SJC  12.1 (7.8)  11.1 (7.2)
DIP involvement,† n (%) 114 (53.5) 101 (47.9)
HAQ-DI   1.3 (0.7)   1.3 (0.7)
Patient Global Assessment of disease activity (VAS 0–100 mm)  61.1 (23.5)  62.6 (22.6)
Physician Global Assessment of disease activity (VAS 0–100 mm)  53.9 (18.8)  55.0 (19.6)
Patient Global Assessment of pain (VAS 0–100 mm)  64.2 (23.5)  64.4 (21.8)
CRP, mg/L  14.0 (20.9)  14.3 (30.3)
Elevated CRP (>ULN‡), n (%) 146 (68.9) 131 (62.7)
DAS28 (CRP)   5.0 (1.1)   4.9 (1.1)
PsA-modified total SHS  20.0 (46.8)  17.7 (39.6)
Psoriasis covering ≥3% BSA, n (%)§ 146 (68.5) 148 (70.1)
PASI score¶**   7.4 (8.0)   7.2 (7.8)
Enthesitis, n (%) 140 (65.7) 132 (62.6)
Dactylitis, n (%)  61 (28.6)  50 (23.7)
Anti-CCP positive (>10 U/mL), n (%)  10 (5.1)   2 (1.0)
Medication use
Prior TNFi, n (%) 129 (60.6) 130 (61.6)
1  94 (44.1)  92 (43.6)
2  31 (14.6)  36 (17.1)
≥3   4 (1.9)   2 (0.9)
Concomitant methotrexate, n (%) 129 (60.6) 127 (60.2)
Concomitant csDMARDs other than methotrexate, n (%)  27 (12.7)  25 (11.8)
Concomitant oral corticosteroids, n (%)**  56 (26.3)  51 (24.2)
Data are presented as mean (SD) unless indicated otherwise.
*For the following assessments, patient numbers in the abatacept and placebo arms, respectively, were as follows: body mass index (212 and 210), HAQ-DI score (212 and 211), 
Patient Global Assessment of disease activity (211 and 210), Physician Global Assessment of disease activity (210 and 209), Patient Global Assessment of pain (213 and 210), 
elevated CRP (212 and 209), DAS28 (CRP) score (210 and 208), PsA-modified total SHS score (205 and 202), PASI score (145 and 148) and anti-CCP positive (196 and 198).
†One or more swollen or tender DIP joint.
‡ULN=3 mg/L.
§Of patients with psoriasis covering ≥3% of BSA in the abatacept and placebo arms, 55 and 51 were in the TNFi-naïve subgroup, and 91 and 97 were in the TNFi-exposed 
subgroup, respectively.
¶Measured only for patients with psoriasis covering ≥3% of BSA.
**Mean (SD) oral daily steroid dose at baseline (prednisone equivalent) abatacept, 6.8 (2.68); placebo, 6.3 (2.56).
BSA, body surface area; CCP, cyclic citrullinated peptide; CRP, C-reactive protein; csDMARD, conventional synthetic disease-modifying antirheumatic drug; DAS28 (CRP), Disease 
Activity Score 28 (C-reactive protein); DIP, distal interphalangeal; HAQ-DI, Health Assessment Questionnaire–Disability Index (range 0–3); PASI, Psoriasis Area and Severity Index 
(range 0–72); PsA, psoriatic arthritis; PsA-modified total SHS, psoriatic arthritis-modified total Sharp/van der Heijde score (range 0–528); SJC, swollen joint count (range 0–66); 
TJC, tender joint count (range 0–68); TNFi, tumour necrosis factor inhibitor; ULN, upper limit of normal; VAS, visual analogue scale.
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were seen in the total population and TNFi-naïve and TNFi-ex-
posed subgroups at week 44 in the ITT analyses (see online 
supplementary figure 2 and table 7 in the supplementary 
appendix).
Structural damage
The proportion of patients without radiographic progression 
at week 24 was 42.7% in the abatacept group versus 32.7% in 
the placebo group (estimated difference (95% CI), 10.0 (1.0 to 
19.1); nominal p=0.034). The mean (SE) change from baseline 
in PsA-modified total SHS score was 0.30 (0.12) versus 0.35 
(0.13) at week 24 for abatacept versus placebo and 0.18 (0.12) 
versus 0.30 (0.12) at week 44/52 for abatacept versus placebo/
abatacept.
Psoriatic skin responses
The psoriatic skin response was more modest compared with 
the musculoskeletal response. At week 24, there was a small 
numerical increase in the proportion of PASI 50 responders 
with abatacept compared with placebo: 26.7% versus 19.6% 
(estimated difference (95% CI), 7.3 (–2.2 to 16.7); nominal 
p=0.137). The proportion of patients with ≥75% improve-
ment in PASI score from baseline (PASI 75 responders) with 
abatacept versus placebo at week 24 was 16.4% versus 10.1%, 
respectively.
The magnitude of improvement in both PASI 50 and PASI 
75 response rates with abatacept versus placebo at week 24 
was numerically greater in the TNFi-naïve compared with the 
TNFi-exposed subgroup: PASI 50 (TNF naïve, 32.7% vs 19.6%; 
Figure 1 Patient disposition. SC, subcutaneous. *Includes missing (n=2).
Table 2 ACR20/50/70 responders in the total population and TNFi-naïve and TNFi-exposed subgroups (ITT population)
Week 24 Week 44
Abatacept Placebo
estimated difference 
(95% CI)
Abatacept/open-label 
abatacept
Placebo/open-label 
abatacept
Total population n=213 n=211 n=213 n=211
ACR20 39.4 22.3 17.2 (8.7 to 25.6)* 48.4 49.3
ACR50 19.2 12.3  6.9 (0.1 to 13.7) 28.2 32.2
ACR70 10.3  6.6  3.7 (–1.5 to 8.9) 15.5 17.5
TnFi naïve n=84 n=81 n=84 n=81
ACR20 44.0 22.2 21.9 (8.3 to 35.6)† 54.8 56.8
ACR50 25.0 14.8 10.2 (–1.5 to 22.0) 35.7 38.3
ACR70 11.9  8.6  3.3 (–5.8 to 12.4) 14.3 23.5
TnFi exposed n=129 n=130 n=129 n=130
ACR20 36.4 22.3 14.0 (3.3 to 24.8)‡ 44.2 44.6
ACR50 15.5 10.8  4.7 (–3.4 to 12.8) 23.3 28.5
ACR70  9.3  5.4  3.9 (–2.4 to 10.2) 16.3 13.8
Data are presented as percentages of patients.
Early escape patients were imputed as non-responders in the week 24 analysis. Estimated differences between original treatment arms were not calculated in the week 44 
analysis.
*p<0.001 versus placebo.
†Nominal p=0.003 versus placebo.
‡Nominal p=0.012 versus placebo.
ACR20, ≥20% improvement in American College of Rheumatology criteria; ACR50, ≥50% improvement in American College of Rheumatology criteria; ACR70, ≥70% 
improvement in American College of Rheumatology criteria; ITT, intent-to-treat; TNFi, tumour necrosis factor inhibitor.
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TNFi exposed, 23.1% vs 19.6%) and PASI 75 (TNFi naïve, 
18.2% vs 9.8%; TNFi exposed, 16.5% vs 10.3%).
In the ITT population at week 44, PASI 50 response rates 
were maintained for patients who continued on abatacept (total 
population, 30.1%; TNFi naïve, 36.4%; TNFi exposed, 26.4%) 
and improved for those who switched from placebo to abatacept 
(total population, 34.5%; TNFi naïve, 39.2%; TNFi exposed, 
32.0%). PASI 75 responses were also maintained for patients 
who continued on abatacept (total population, 19.9%; TNFi 
naïve, 27.3%; TNFi exposed, 15.4%) and improved for the 
placebo/abatacept group (total population, 16.9%; TNFi naïve, 
17.6%; TNFi exposed, 16.5%).
disease activity—composite measures
The proportion of patients with MDA at week 24 was numeri-
cally higher with abatacept versus placebo in the total population 
(11.7% vs 8.1%; nominal p=0.205). At week 52, the propor-
tion of patients with MDA increased to 17.4% for patients who 
continued on abatacept and 18.5% for the placebo/abatacept 
group. Similar trends were observed in the modified Composite 
Psoriatic Disease Activity Index and Psoriatic Arthritis Disease 
Activity Score (see online section 4 in the supplementary 
appendix). There was a nominally significant improvement with 
abatacept versus placebo in adjusted mean change from base-
line to week 24 in DAPSA score (–18.75 vs –13.00; adjusted 
difference –5.75; 95% CI –10.01 to –1.49; nominal p=0.008). 
At week 44, further improvements in adjusted mean change 
from baseline in DAPSA score were observed in the abatacept 
and placebo/abatacept groups (–24.58 and –25.18, respectively).
Quality of life
At 24 weeks, mean improvements from baseline were numerically 
greater with abatacept versus placebo for SF-36 physical compo-
nent summary and Dermatology Life Quality Index scores but 
were similar between the two groups for SF-36 mental compo-
nent summary scores. Similar results were also seen at week 52 
(see online table 8 in the supplementary appendix).
Safety
Safety findings during the 24-week, double-blind period and for 
cumulative abatacept treatment over the 52-week study period 
are summarised in table 3. During the 24-week, double-blind 
period, the abatacept and placebo groups had similar safety 
profiles, with comparable incidences, respectively, of serious AEs 
(2.8% vs 4.3%), AEs (54.5% vs 53.1%) and infections (26.8% 
vs 29.9%). One serious infection (Pneumocystis jirovecii) was 
considered related to study drug by the investigator and led 
to treatment discontinuation. This event occurred during the 
double-blind period in a patient receiving abatacept who had a 
history of smoking and chronic obstructive pulmonary disease 
and had recently used high-dose corticosteroids. The episode 
resolved after 7 days of appropriate treatment.
dISCuSSIOn
In this phase III study, selective modulation of T-cell costimu-
lation with abatacept resulted in significantly higher ACR20 
response rates in patients with PsA compared with placebo, with 
responses maintained to at least 1 year. Our findings support 
previous data suggesting a role for T cells in PsA: activated T 
cells are abundant in the synovial fluid of patients with PsA31 32 
and frequencies of interleukin (IL)-17-secreting CD8+ T cells 
are increased in erosive disease.32 Furthermore, treatment with 
abatacept has been shown to reduce circulating IL-17-secreting 
CD4+ and CD8+ T cells in RA.33 The data reported here 
suggest that selective inhibition of the CD28-dependent costim-
ulatory pathway critical for T-cell activation7 may offer a novel 
treatment option in PsA.
Our findings demonstrate that abatacept had an overall bene-
ficial effect on musculoskeletal symptoms and was well toler-
ated in a relatively refractory population of patients with PsA 
(approximately 60% had received prior TNFi), confirming 
earlier results from a phase II, dose-ranging study in a less refrac-
tory population (approximately 30% of patients in the abata-
cept 10 mg/kg and placebo groups had received prior TNFi).15 
The primary end point was met, with a statistically significantly 
Figure 2 ACR20 response over the 24-week double-blind period (non-responder imputation for early escape). Early escape patients switching to 
open-label abatacept at week 16 were imputed as non-responders at weeks 20 and 24. If there were still missing data, patients were imputed as non-
responders, unless data were missing between two time points at which the patient had a response, in which case response was imputed. #Where 
95% CI of estimate of differences in ACR20 responses for abatacept versus placebo do not contain zero. ACR20, ≥20% improvement in the American 
College of Rheumatology criteria.
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higher ACR20 response at 24 weeks with abatacept treatment 
versus placebo. Although numerical improvements in indi-
vidual ACR core components were observed with abatacept 
versus placebo at 24 weeks, the CIs were overlapping. Due to 
the lack of significant effect on HAQ-DI response rates in the 
total population, it was not possible to attribute significance to 
lower-ranking outcomes in the statistical hierarchy. The efficacy 
in joints was supported by mean improvements in DAS28 (CRP) 
with abatacept versus placebo. In addition, disease improvement 
was evident when placebo-treated patients switched to abata-
cept. Outcomes tended to be better in the TNFi-naïve versus 
TNFi-exposed subgroups.
Across end points up to week 52, responses were maintained 
or improved for patients who continued on abatacept, demon-
strating the durability of effects and accrual of benefits over time 
on some measures. For patients who switched from placebo to 
open-label abatacept, it is possible that observed improvements 
could at least partially be explained by patient awareness of 
receiving active treatment, or a continuation of trends during 
receipt of placebo, rather than a true treatment effect. However, 
the similar ACR20 response rates at 44 weeks for patients who 
Figure 3 Proportion of patients achieving ACR20 response (ITT 
analysis, actual data for early escape patients) over the combined 
double-blind and open-label periods in the total population (A) and the 
TNFi-naïve (B) and TNFi-exposed (C) subgroups. Error bars represent 
95% CIs. For EE patients, measurements at weeks 20, 24, 28, 36 and 
44 are actual measurements at weeks 4, 8, 12, 20 and 28 of open-
label abatacept treatment. The increase in the proportion of patients 
with ACR20 response from week 16 to week 24 in the placebo group 
reflects the mixed population of EE patients who received abatacept 
between weeks 16 and 24 and non-EE patients who received placebo 
at week 24. If there were missing data, patients were imputed as 
non-responders, unless data were missing between two time points at 
which the patient had a response, in which case response was imputed. 
ACR20, ≥20% improvement in the American College of Rheumatology 
criteria; EE, early escape; ITT, intent to treat; TNFi, tumour necrosis factor 
inhibitor.
Table 3 Summary of safety
double-blind period* Week 52†
Abatacept
 (n=213)
Placebo
 (n=211)
Cumulative abatacept 
population (n=398)
Deaths   0   0   0
SAEs   6 (2.8)   9 (4.3)  34 (8.5)
Treatment related   1 (0.5)‡   1 (0.5)   5 (1.3)§
Leading to discontinuation   3 (1.4)   3 (1.4)   8 (2.0)¶
AEs 116 (54.5) 112 (53.1) 273 (68.6)
Treatment related  33 (15.5)  24 (11.4)  81 (20.4)
Leading to discontinuation   3 (1.4)   4 (1.9)  13 (3.3)
AEs reported in ≥5% of 
patients
Nasopharyngitis   9 (4.2)  11 (5.2)  25 (6.3)
Upper RTI   6 (2.8)  14 (6.6)  28 (7.0)
Bronchitis   7 (3.3)   5 (2.4)  26 (6.5)
AEs of special interest
Infections  57 (26.8)  63 (29.9) 162 (40.7)
Malignancies   0   2 (0.9)   4 (1.0)
Autoimmune events   0   0   1 (0.3)
Local ISRs   1 (0.5)   1 (0.5)   5 (1.3)
Data are presented as n (%) of patients.
Investigators were instructed not to report psoriasis or psoriatic arthritis as AEs 
unless they were new forms of psoriasis or SAEs.
*Includes data up to 56 days after the last dose in the double-blind period or the 
first dose in the open-label period, whichever occurred first.
†Includes data from the first day of the double-blind period for patients in the 
abatacept group and from the first day of the open-label period for patients treated 
initially with placebo up to 56 days after the last abatacept dose up to week 52.
‡Pneumocystis jirovecii infection (see text).
§Pyelonephritis (n=1), dyspnoea (n=1), erythrodermic psoriasis (n=1), transitional 
cell carcinoma (n=1), plus the event of P. jirovecii infection in the double-blind 
period. The event of erythrodermic psoriasis occurred following treatment with 
topical corticosteroids and intramuscular dexamethasone in a female patient with 
severe plaque psoriasis at baseline (PASI score=27.6); the patient had discontinued 
earlier from the study due to lack of efficacy.
¶Gastroenteritis (n=1), P. jirovecii infection (n=1), prostate cancer (n=1), 
transitional cell carcinoma (n=1), uterine leiomyoma (n=1), colitis (n=1), biliary 
dilatation plus an AE of upper abdominal pain (n=1) and interstitial lung disease 
(n=1).
AE, adverse event; ISR, injection-site reaction; PASI, Psoriasis Area and Severity 
Index (range 0–72); RTI, respiratory tract infection; SAE, serious adverse event.
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started on abatacept and those who switched from placebo to 
abatacept indicate a treatment effect and benefit after switching.
Skin responses to abatacept were modest. A small treatment 
effect on skin manifestations has previously been observed with 
the T-cell inhibitor, alefacept, in a phase III study in psoriasis.34 
It is also possible that a higher dose of abatacept may be required 
for optimal efficacy in skin versus musculoskeletal symptoms, 
similar to previous findings with the TNFi etanercept.35
Caution is advised when comparing the current efficacy data 
with findings from studies of TNFi and other agents in PsA. 
The ACR20 response rate at week 24 in this study was lower 
than that in previous studies of agents that target some of the 
known effector molecules in PsA.36–38 However, this study 
included a higher proportion of TNFi failures compared with 
most studies,36 37 which may indicate a more treatment-refrac-
tory population, as noted previously.39 Higher efficacy in the 
TNF-naive compared with the TNFi-exposed subgroup across 
multiple end points in the current study confirmed the treat-
ment resistance in the latter subpopulation. In contrast to find-
ings with other agents with different mechanisms of action,36–38 
abatacept treatment demonstrated better efficacy on musculo-
skeletal versus skin end points. The reasons for this are unclear 
but may include differential dose requirements for optimal effi-
cacy of abatacept in skin versus the joints, for example, due to 
less efficient drug penetration of skin versus synovial tissue, and 
distinct pathologies with divergent roles of T cells and T-cell 
subsets in skin versus synovial inflammation in PsA. Regarding 
the latter, it is interesting to note that, in PsA, agents targeting 
the IL-23/IL-17 axis can achieve complete clearing of psoriatic 
skin lesions without a similar level of efficacy in the joints.40 
We speculate that T-cell subsets driving pathology in the skin 
and joints may differ in their expression of CD28 and, hence, 
susceptibility to abatacept.
In this study, subcutaneous abatacept was well tolerated with 
no new safety signals, consistent with the phase II study of 
intravenous abatacept in PsA15 and previous studies of subcu-
taneous and intravenous abatacept in RA.41 Throughout the 
study, one serious opportunistic infection was reported. This 
case of P. jirovecii infection occurred in the abatacept arm in 
a patient who had a history of smoking and chronic obstruc-
tive pulmonary disease and had recently received high doses of 
corticosteroids. It has been recognised that patients with chronic 
obstructive pulmonary disease have an increased prevalence of 
Pneumocystis colonisation, which may predispose them to acute 
infection.42
Limitations of this study include the prespecified imputation 
method used to measure radiographic progression. Imputation 
as radiographic progressors of patients who escaped early to 
open-label abatacept, based on poor clinical response at week 
16, led to a relatively high imputed rate of structural progres-
sion at week 24 in both groups. This imputation method that 
was designed initially is inappropriate as it assumed that the 
structural radiographic data behaved similarly to clinical data 
and obscured underlying rates of radiographic change. Overall, 
there was minimal progression based on the mean change from 
baseline in PsA-modified total SHS score over 24 and 44/52 
weeks in both groups, making it difficult to detect meaningful 
treatment differences. In this context, it should be noted that, in 
the phase II study in PsA, abatacept demonstrated greater inhi-
bition of structural damage versus placebo as well as improve-
ments in joint inflammation on MRI over the same timeframe 
(24 weeks).15
In summary, abatacept treatment achieved the primary 
end point in ACR20 response rates in patients with PsA, of 
whom ~60% had prior exposure to TNFi agents. There were 
trends towards benefits in other musculoskeletal measures, with 
maximal effects seen in the TNFi-naïve patients. However, only 
modest benefit was demonstrated for psoriatic skin lesions. 
Abatacept was well tolerated with no new safety signals.
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